Transforming growth factor-beta: new chemical forms and new biological roles.
Explore the source record for details and available documents.
Animals↗
Biomedical subjects
A B Roberts
Publications and source records attributed to A B Roberts.
Increased expression of growth factor mRNAs accompanies viral transformation of rodent cells.
Transforming growth factors-alpha and beta (TGF-alpha and -beta) and platelet-derived growth factor (PDGF), three distinct peptide hormones, acting together, are able to potentiate the phenotypic transformation of normal rat kidney (NRK) cells. Cells transformed by retroviruses have been shown to secrete increased levels of TGF-alpha, TGF-beta and PDGF. We report here that Harvey sarcoma virus-transformed NIH-3T3 cells and Moloney sarcoma virus-transformed NRK cells show increased expression of the mRNAs for TGF-alpha, TGF-beta, PDGF A-chain and nerve growth factor (NGF) compared to their untransformed counterparts. No amplification or rearrangement in the genomic DNA is seen in the transformed cells. In tumor tissue formed by subcutaneous injection of Ha-3T3 cells, this enhanced level of TGF-beta mRNA returns to the control level of the untransformed cells. The increase in TGF-beta mRNA in the transformed cells is paralleled by an increase in the level of TGF-beta protein as shown by immunoprecipitation and Western blotting procedures using specific TGF-beta antibodies.
Animals↗
Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines.
Steady state mRNA levels for transforming growth factor beta, platelet-derived growth factor (PDGF) A-chain, and PDGF B-chain were measured in normal human mesothelial cells, SV40 large T-antigen expressing human mesothelial cells, and human mesothelioma cell lines. The mRNA expression level for transforming growth factor beta was similar in all three types of culture while normal human mesothelial cells secrete more transforming growth factor beta than do mesothelioma cell lines or T-antigen expressing mesothelial cells. In contrast, both PDGF A- and B-chain mRNAs are expressed at higher levels in mesothelioma cell lines than in normal human mesothelial cells. PDGF-like mitogenic activity was readily detectable in medium conditioned by a mesothelioma cell line and was undetectable in conditioned medium from normal cells. These results suggest the hypothesis that PDGF may be an autocrine growth factor in mesothelioma.
Cell Line↗
Membrane binding characteristics of two forms of transforming growth factor-beta.
Cartilage-inducing factors A and B (CIF-A and CIF-B) from bovine bone have recently been identified as transforming growth factor-beta (TGF-beta) (Seyedin, S.M., Thompson, A. Y., Bentz, H., Rosen, D. M., McPherson, J. M., Conti, A., Siegel, N. R., Galluppi, G. R., and Piez, K. A. (1986) J. Biol. Chem., 261, 5693-5695) and a unique protein homologous to TGF-beta (Seyedin S. M., Segarini, P. R., Rosen, D. M., Thompson, A. Y., Bentz, H., and Graycar, J. (1987) J. Biol. Chem., 262, 1946-1949), respectively. Although the biological activities of TGF-beta and CIF-B are similar, the divergence of CIF-B from the highly conserved amino acid sequence of TGF-beta prompted an investigation of its receptor binding properties. Three classes of cell surface binding components were identified. Class A has exclusive affinity for TGF-beta; class B has greater affinity for CIF-B; and class C has equal affinity for both proteins. A high molecular weight component, the predominant binding species, was further characterized and shown to consist of two components that are either class B or class C. The differential binding properties of TGF-beta and CIF-B to cell surface components suggest that there are biological activities unique to each of the proteins.
Binding, Competitive↗
Transforming growth factor beta levels in rat wound chambers.
Exogenous TGF-beta accelerates healing in both normal and doxorubicin-treated rats, but whether it plays an intrinsic role in the natural healing process is unknown. Subcutaneous wound chambers in 16 F344 rats were aspirated from postwounding Day 3 through Day 16 for TGF-beta levels and cytology. A soft agar assay and a competitive radioreceptor binding assay were used to determine TGF-beta levels. Papanicolau staining and differential cell counts were used to determine cytology. Results were similar using either method for the determination of TGF-beta levels. With the sensitive radioreceptor assay, low TGF-beta levels on postwounding Day 4, mean 2.6 ng/ml, rose to a peak mean level of 20.4 ng/ml on Day 7 and fell significantly from peak level to a level of 5.4 ng/ml of Day 16. All TGF-beta levels for postwounding Days 6 through 14 were significantly increased over the baseline TGF-beta levels of Days 4 and 5 (P less than 0.05). Day 16 TGF-beta levels were not different from baseline. Cytologic changes were characterized by a liner decrease in total neutrophil count over the exam period and a concurrent linear increase in total lymphocyte and macrophage counts. TGF-beta levels changed in a bell-shaped temporal sequence during healing, apparently unrelated to percentage lymphocyte, macrophage, or neutrophil count. Peak TGF-beta levels occurred during the fibroblast proliferation and collagen synthesis phase of healing. This study presents the first evidence that TGF-beta is present in a healing wound and suggests that it may be an intrinsic mediator of the healing process.
Animals↗
Transforming growth factor-beta: potential common mechanisms mediating its effects on embryogenesis, inflammation-repair, and carcinogenesis.
In conclusion, we have demonstrated that a single growth factor, TGF-beta, can act in either an autocrine or paracrine mode to bring about, either directly or indirectly, all of the complex events which together lead to the formation of granulation tissue and tumor stroma. All of the participating cell types, lymphocytes, macrophages, endothelial cells, and fibroblasts have receptors for TGF-beta and many of them secrete TGF-beta as well. Although other growth factors such as platelet-derived growth factor and fibroblast growth factor clearly also participate in these processes, we have shown that TGF-beta, alone, is sufficient to initiate the cascade of events, probably through its ability to chemoattract and to activate macrophages and fibroblasts. Without question, neovascularization and appropriately timed matrix synthesis and degradation are central to embryogenesis as well. Fibronectin, in particular, has been shown to promote cell adhesion and cell migration throughout embryogenesis (Hynes and Yamada, 1982; Rovasio et al., 1983). We propose that TGF-beta will be found to be an important mediator of embryonic development, not only by control of angiogenesis and matrix synthesis, but also by exerting direct local effects on cellular growth and differentiation (reviewed in Roberts and Sporn, 1987).
Animals↗
Transforming growth factor type beta induces monocyte chemotaxis and growth factor production.
Recent studies have focused on the potential role of transforming growth factor type beta (TGF-beta) as an immunoregulatory peptide. In this context, we demonstrate that TGF-beta is a potent chemoattractant for human peripheral blood monocytes. At concentrations from 0.1 to 10 pg/ml, TGF-beta induces directed monocyte migration in vitro. Consistent with this observation is the expression of high-affinity TGF-beta receptors on the monocytes with a Kd of 1-10 pM. At higher concentrations of TGF-beta (greater than or equal to 1 ng/ml), monocytes are stimulated to generate biologically active mediator(s) that enhance fibroblast growth. Gene expression for one of these growth factors, interleukin 1, is induced in monocytes within hours after exposure to TGF-beta. Thus, TGF-beta may provide an important signal for monocyte recruitment and for regulation of their synthesis of mediators of fibroblast growth and activity in wound healing.
Chemotaxis, Leukocyte↗
Osteoblasts synthesize and respond to transforming growth factor-type beta (TGF-beta) in vitro.
Transforming growth factor-type beta (TGF-beta) has been identified as a constituent of bone matrix (Seyedin, S. M., A. Y. Thompson, H. Bentz, D. M. Rosen, J. M. McPherson, A. Conti, N. R. Siegel, G. R. Gallupi, and K. A. Piez, 1986, J. Biol. Chem. 261:5693-5695). We used both developing bone and bone-forming cells in vitro to demonstrate the cellular origin of this peptide. TGF-beta mRNA was detected by Northern analysis in both developing bone tissue and fetal bovine bone-forming cells using human cDNA probes. TGF-beta was shown to be synthesized and secreted by metabolically labeled bone cell cultures by immunoprecipitation from the medium. Further, TGF-beta activity was demonstrated in conditioned media from these cultures by competitive radioreceptor and growth promotion assays. Fetal bovine bone cells (FBBC) were found to have relatively few TGF-beta receptors (5,800/cell) with an extremely low Kd of 2.2 pM (high binding affinity). In contrast to its inhibitory effects on the growth of many cell types including osteosarcoma cell lines, TGF-beta stimulated the growth of subconfluent cultures of FBBC; it had little effect on the production of collagen by these cells. We conclude that bone-forming cells are a source for the TGF-beta that is found in bone, and that these cells may be modulated by this factor in an autocrine fashion.
Animals↗
Some recent advances in the chemistry and biology of transforming growth factor-beta.
Explore the source record for details and available documents.
Animals↗
Role of transforming growth factor-beta in the development of the mouse embryo.
Using immunohistochemical methods, we have investigated the role of transforming growth factor-beta (TGF-beta) in the development of the mouse embryo. For detection of TGF-beta in 11-18-d-old embryos, we have used a polyclonal antibody specific for TGF-beta type 1 and the peroxidase-antiperoxidase technique. Staining of TGF-beta is closely associated with mesenchyme per se or with tissues derived from mesenchyme, such as connective tissue, cartilage, and bone. TGF-beta is conspicuous in tissues derived from neural crest mesenchyme, such as the palate, larynx, facial mesenchyme, nasal sinuses, meninges, and teeth. Staining of all of these tissues is greatest during periods of morphogenesis. In many instances, intense staining is seen in mesenchyme when critical interactions with adjacent epithelium occur, as in the development of hair follicles, teeth, and the submandibular gland. Marked staining is also seen when remodeling of mesenchyme or mesoderm occurs, as during formation of digits from limb buds, formation of the palate, and formation of the heart valves. The presence of TGF-beta is often coupled with pronounced angiogenic activity. The histochemical results are discussed in terms of the known biochemical actions of TGF-beta, especially its ability to control both synthesis and degradation of both structural and adhesion molecules of the extracellular matrix.
Animals↗
Transforming growth factor-beta: selective increase in glycosaminoglycan synthesis by cultures of fibroblasts from patients with progressive systemic sclerosis.
Transforming growth factor-beta (TGF-beta) has been found in all cells examined thus far, and has been shown to play an important role in inflammation and connective tissue formation. We now report that TGF-beta, alone or in combination with epidermal growth factor (EGF), led to a preferential increase in glycosaminoglycan synthesis by cultures of dermal fibroblasts from patients with progressive systemic sclerosis (PSS) when compared with normal fibroblasts (p less than 0.001). Transforming growth factor-beta increased collagen synthesis to the same extent in both PSS and normal fibroblasts, whereas EGF had no stimulatory activity on collagen synthesis. The addition of EGF to cultures incubated with TGF-beta led to a decrease in collagen synthesis compared with the effect seen with TGF-beta alone (p less than 0.02). These studies suggest that TGF-beta may play an important role in the accumulation of connective tissue seen in PSS and that the combined action of multiple growth factors may modulate the synthetic activity of human dermal fibroblasts.
Cells, Cultured↗
Peptide growth factors: current status and therapeutic opportunities.
Explore the source record for details and available documents.
Animals↗
Relationship between fetal growth and maternal fructosamine in diabetic pregnancy.
We studied 30 diabetic pregnant women to compare serum fructosamine concentrations at different stages of gestation with fetal growth (as determined by ultrasonography) and with birth weight. Serum fructosamine levels in mothers of macrosomic infants were significantly higher (P less than .05) during the first trimester of pregnancy as compared with mothers of normal birth weight infants. Moreover, first-trimester fructosamine concentrations correlated significantly with birth weight (r = 0.68, P less than .001) and with ultrasound measurements of fetal abdominal circumference and femur length. The fetus destined to be macrosomic had an enlarged abdomen in the second trimester, often before 20 weeks' gestation. We conclude that maternal diabetic control during early gestation has an important influence on fetal growth and contributes to the development of fetal macrosomia.
Adult↗
Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes.
The growth and differentiation of B cells to immunoglobulin (Ig)-secreting cells is regulated by a variety of soluble factors. This study presents data that support a role for transforming growth factor (TGF)-beta in this regulatory process. B lymphocytes were shown to have high-affinity receptors for TGF-beta that were increased fivefold to sixfold after in vitro activation. The addition of picogram quantities of TGF-beta to B cell cultures suppressed factor-dependent, interleukin 2 (IL 2) B cell proliferation and markedly suppressed factor-dependent (IL 2 or B cell differentiation factor) B cell Ig secretion. In contrast, the constitutive IgG production by an Epstein Barr virus-transformed B cell line was not modified by the presence of TGF-beta in culture. This cell line was found to lack high-affinity TGF-beta receptors. The degree of inhibition of B cell proliferation observed in in vitro cultures was found to be dependent not only on the concentration of TGF-beta added but also on the concentration of the growth stimulatory substance (IL 2) present. By increasing the IL 2 concentrations in culture, the inhibition of proliferation induced by TGF-beta could be partially overcome. In contrast, the inhibition of Ig secretion induced by TGF-beta could not be overcome by a higher concentration of stimulatory factor, demonstrating that the suppression of B cell differentiation by TGF-beta is not due solely to its effects on proliferation. Furthermore, it was demonstrated that B lymphocytes secrete TGF-beta. Unactivated tonsillar B cells had detectable amounts of TGF-beta mRNA on Northern blot analysis, and B cell activation with Staphylococcus aureus Cowan (SAC) resulted in a twofold to threefold increase in TGF-beta mRNA. Supernatants conditioned by unactivated B cells had small amounts of TGF-beta, SAC activation of the B cells resulted in a sixfold to sevenfold increase in the amount of TGF-beta present in the supernatants. Thus, B lymphocytes synthesize and secrete TGF-beta and express receptors for TGF-beta. The addition of exogenous TGF-beta to cultures of stimulated B cells inhibits subsequent proliferation and Ig secretion. TGF-beta may function as an autocrine growth inhibitor that limits B lymphocyte proliferation and ultimate differentiation.
Adolescent↗
Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells.
Transforming growth factor-beta (TGF-beta) is now known to have a number of actions in addition to the induction of phenotypic transformation in fibroblastic cells. In this paper, we characterize its inhibition of differentiation in rat myoblasts of Yaffe's L6 strain and demonstrate its identity or very close similarity to the differentiation inhibitor (DI) secreted by Buffalo rat liver cells cultured in serum-free medium. At concentrations as low as 60 pg/ml, TGF-beta gave detectable inhibition of differentiation measured as myoblast fusion and creatine kinase elevation; maximal inhibition was observed at and above 0.5 ng/ml (20 pM). The inhibition persisted as long as fresh TGF-beta was added at 48-h intervals, but it was reversed upon removal of the factor. By itself or in the presence of mitogens, TGF-beta had no mitogenic activity in the L6 cells. Concentration dependencies of human TGF-beta and the rat DI were closely parallel in three assays: inhibition of myoblast differentiation, stimulation of normal rat kidney cell growth in soft agar, and competition for displacement of labeled TGF-beta from binding sites on A549 human lung carcinoma cells. We conclude that most if not all of the DI activity found in medium conditioned by Buffalo rat liver cells can be attributed to the presence of TGF-beta or a very similar molecule. These observations also offer a potentially useful approach to study the control of myogenesis; the process(es) can be blocked in cloned L6 myoblasts by incubation with very small quantities of a pure protein in fully defined serum-free medium.
Animals↗
Transforming growth factor-beta: biological function and chemical structure.
Transforming growth factor-beta (TGF-beta) is a multifunctional peptide that controls proliferation, differentiation, and other functions in many cell types. Many cells synthesize TGF-beta and essentially all of them have specific receptors for this peptide. TGF-beta regulates the actions of many other peptide growth factors and determines a positive or negative direction of their effects. Its marked ability to enhance formation of connective tissue in vivo suggests several therapeutic applications.
Animals↗
Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.
Type beta transforming growth factor (TGF-beta) is a unique polypeptide that has been isolated from a number of different tissues and can induce the phenotypic transformation of non-neoplastic fibroblasts as measured by the stimulation of their growth in soft agar. Recently, TGF-beta has been demonstrated to exert profound inhibitory effects on T and B lymphocyte proliferation. In this study, the effects of TGF-beta on natural killer (NK) cell function were investigated. After 20 hr of culture in the presence of TGF-beta, the NK activity of peripheral blood lymphocytes (PBL) was significantly reduced compared with PBL cultured in medium alone. Similarly, TGF-beta produced a significant depression in the cytolytic activity of highly enriched large granular lymphocytes (LGL). This effect of TGF-beta appeared to be mediated directly on the effector cells, because cultivation of the K562 target cells in TGF-beta did not affect target cell susceptibility to lysis. Binding studies with 125I-TGF-beta indicated that LGL possess approximately 1400 high-affinity (Kd = 1PM) receptors/cell, which represents a considerably higher affinity receptor for TGF-beta than that found on fibroblasts. Culturing of PBL and LGL in TGF-beta resulted in a marked blunting of the boosting of NK cytolysis by interferon-alpha but not by interleukin 2, which suggested that TGF-beta may down-regulate interferon-alpha receptors on NK cells. These results, indicate that in addition to inhibitory effects on T and B cells, TGF-beta also inhibits NK cell function. Although the in vivo role of TGF-beta is presently undefined, it may be an important immunoregulatory protein that has a negative influence on lymphocyte activation.
Cells, Cultured↗
Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.
This study examines the potential role of transforming growth factor beta (TGF-beta) in the regulation of human T lymphocyte proliferation, and proposes that TGF-beta is an important autoregulatory lymphokine that limits T lymphocyte clonal expansion, and that TGF-beta production by T lymphocytes is important in T cell interactions with other cell types. TGF-beta was shown to inhibit IL-2-dependent T cell proliferation. The addition of picograms amounts of TGF-beta to cultures of IL-2-stimulated human T lymphocytes suppressed DNA synthesis by 60-80%. A potential mechanism of this inhibition was found. TGF-beta inhibited IL-2-induced upregulation of the IL-2 and transferrin receptors. Specific high-affinity receptors for TGF-beta were found both on resting and activated T cells. Cellular activation was shown to result in a five- to sixfold increase in the number of TGF-beta receptors on a per cell basis, without a change in the affinity of the receptor. Finally, the observations that activated T cells produce TGF-beta mRNA and that TGF-beta biologic activity is present in supernatants conditioned by activated T cells is strong evidence that T cells themselves are a source of TGF-beta. Resting T cells were found to have low to undetectable levels of TGF-beta mRNA, while PHA activation resulted in a rapid increase in TGF-beta mRNA levels (within 2 h). Both T4 and T8 lymphocytes were found to make mRNA for TGF-beta upon activation. Using both a soft agar assay and a competitive binding assay, TGF-beta biologic activity was found in supernatants conditioned by T cells; T cell activation resulted in a 10-50-fold increase in TGF-beta production. Thus, TGF-beta may be an important antigen-nonspecific regulator of human T cell proliferation, and important in T cell interaction with other cell types whose cellular functions are modulated by TGF-beta.
Antigens, Differentiation, T-Lymphocyte↗